Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction

Annals of Medicine

Volumn 43, Issue 1, 2011, Pages 60-68

  De Boer, Rudolf A ^a   Lok, Dirk J A ^b   Jaarsma, Tiny ^a   Van Der Meer, Peter ^a   Voors, Adriaan A ^a   Hillege, Hans L ^a   Van Veldhuisen, Dirk J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b DEVENTER HOSPITAL   (Netherlands)

Author keywords

Biomarkers; galectin 3; heart failure; prognosis; remodeling

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; GALECTIN 3; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PREDICTIVE VALIDITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; DIURETICS; FEMALE; GALECTIN 3; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE VOLUME; TREATMENT OUTCOME;

EID: 78651387589     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2010.538080     Document Type: Article

References (30)

1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al.; for ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388-442.
2. De Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail. 2009;11:811-7.
3. Yang RY, Rabinovich GA, Liu FT. Galectins: Structure, function and therapeutic potential. Expert Rev Mol Med. 2008;13:e17-39.
4. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110: 3121-8.
5. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006;48:1217-24.
6. Lok DJA, van der Meer P, Bruggink-Andréde la Porte PW, Lipsic E, van Wijngaarden J, Hillege JL, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010;99:323-8.
7. Milting H, Ellinghaus P, Seewald M, Cakar H, Bohms B, Kassner A, et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant. 2008;27:589-96.
8. Lin YH, Lin LY, Wu YW, Chien KL, Lee CM, Hsu RB, et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta. 2009;409:96-9.
9. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RRJ, Januzzi JL. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompen-sated heart failure. Eur J Heart Fail. 2010;12:826-32.
10. Jaarsma T, Van Der Wal MH, Hogenhuis J, Lesman I, Luttik ML, Veeger NJ, et al. Design and methodology of the COACH study: a multicenter randomised coordinating study evaluating advising and counseling in heart failure. Eur J Heart Fail. 2004;6:227-33.
11. Jaarsma T, van der Wal MHL, Lesman-Leegte I, Luttik M, Hogenhuis J, Veeger NJ, et al.; for the coordinating study evaluating outcomes of advising and counseling in heart failure (COACH). Effect of moderate or intensive disease management on outcome in patients with heart failure. Coordinating study evaluating outcomes of advising and counseling in heart failure (COACH). Arch Int Med. 2008;168:316-24.
12. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777-81.
13. Christenson RH, Duh SH, Wu AH, Smith A, Abel G, Defi lippi CR, et al. Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure. Clin Biochem. 2010;43:683-90.
14. Reifenberg K, Lehr HA, Torzewski M, Steige G, Wiese E, Küpper I, et al. Interferon- γ induces chronic active myocarditis and cardiomyopathy in transgenic mice. Am J Pathol. 2007;171:463-72.
15. Thandavarayan RA, Watanabe K, Ma M, Veeraveedu PT, Gurusamy N, Palaniyandi SS, et al. 14-3-3 protein regulates Ask1 signaling and protects against diabetic cardiomyopathy. Biochem Pharmacol. 2008;75:1797-806.
16. Sharma U, Rhaleb NE, Pokharel S, Harding P, Rasoul S, Peng H, et al. Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. Am J Physiol. 2008;294:H1226-32.
17. Masson S, Latini R, Anand IS, Barlera S, Angelici L, Vago T, et al.; Val-HeFT Investigators. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol. 2008;52: 997-1003.
18. Faggiano P, Valle R, Aspromonte N, D'Aloia A, Di Tano G, Barro S, et al. How often we need to measure brain natriu-retic peptide (BNP) blood levels in patients admitted to the hospital for acute severe heart failure? Role of serial measurements to improve short-term prognostic stratifi cation. Int J Cardiol. 2010;140:88-94.
19. Hsu DK, Chen H, Liu FT. Galectin-3 regulates T-cell functions. Immunol Rev. 2009;230:114-27.
20. Dhirapong A, Lleo A, Leung P, Gershwin ME, Liu FT. The immunological potential of galectin-1 and -3. Autoimmun Rev. 2009;8:360-3.
21. Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev. 2009;230:160-71.
22. Wedel H, McMurray JJ, Lindberg M, Wikstrand J, Cleland JG, Cornel JH, et al.; CORONA Study Group. Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail. 2009;11:281-91.
23. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 2000; 102:3060-7.
24. De Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep. 2010; 7:1-8.
25. van Veldhuisen DJ, Cohen-Solal A, Böhm M, Anker SD, Babalis D, Roughton M, et al.; SENIORS Investigators. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol. 2009; 53:2150-8.
26. Kindermann M, Reil JC, Pieske B, van Veldhuisen DJ, Böhm M. Heart failure with normal left ventricular ejection fraction: what is the evidence? Trends Cardiovasc Med. 2008;18:280-92.
27. Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28:2539-50.
28. Kirk V, Bay M, Parner J, Krogsgaard K, Herzog TM, Boesgaard S, et al. N-terminal proBNP and mortality in hospitalised patients with heart failure and preserved vs. reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure Study (CHHF). Eur J Heart Fail. 2004;6:335-41.
29. Grewal J, McKelvie RS, Persson H, Tait P, Carlsson J, Swedberg K, et al. Usefulness of N-terminal pro-brain natri-uretic peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. Am J Cardiol. 2008;102:733-7.
30. Martos R, Baugh J, Ledwidge M, O'Loughlin C, Murphy NF, Conlon C, et al. Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. Eur J Heart Fail. 2009;11:191-7.